Daprodustat: A potential game-changer in renal anemia therapy-A perspective
The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2023-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_abdd093a06154bc29e5fc2c97cb94e95 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Muhammad Usman Haider |e author |
| 700 | 1 | 0 | |a Muhammad Furqan |e author |
| 700 | 1 | 0 | |a Qasim Mehmood |e author |
| 245 | 0 | 0 | |a Daprodustat: A potential game-changer in renal anemia therapy-A perspective |
| 260 | |b Frontiers Media S.A., |c 2023-08-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2023.1249492 | ||
| 520 | |a The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials. | ||
| 546 | |a EN | ||
| 690 | |a anemia | ||
| 690 | |a chronic kidney disease | ||
| 690 | |a daprodustat | ||
| 690 | |a HIF | ||
| 690 | |a renal disease | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 14 (2023) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1249492/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/abdd093a06154bc29e5fc2c97cb94e95 |z Connect to this object online. |